Pikavation Therapeutics Acquired by Novartis — Healthcare M&A

Novartis has completed the acquisition of Pikavation Therapeutics, a pharmacy business in the United States, for $3 billion. Novartis acquisitions focus on expanding healthcare M&A capabilities in prescription drug development, and Pikavation Therapeutics is positioned as a biotech platform targeting unmet medical needs. The Novartis acquires Pikavation Therapeutics strategy supports a strategic acquisition pipeline in pharmacy and strengthens merger acquisition execution across healthcare. The announced merger acquisition is a strategic acquisition by Novartis, with deal size over $100M and a $3 billion consideration, subject to customary closing conditions.